Agenus Inc. [NASDAQ: AGEN] plunged by -$0.15 during the normal trading session on Friday and reaching a high of $3.84 during the day while it closed the day at $3.55. The company report on December 3, 2020 that Completion of Balstilimab BLA Filing Extended To 1H2021.
Agenus to fulfill FDA feedback for six-month follow-up on late responders.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced updated timing of the balstilimab BLA filing to meet the FDA feedback to follow all patients for a median of 12 months and responders for a minimum of 6 months. Due to two newly-identified late responses in the trial, the completion of the BLA filing is planned for the first half of 2021. In parallel, Agenus is working with the FDA to clarify diagnostic requirements for PD-L1 testing.
Agenus Inc. stock has also gained 3.20% of its value over the past 7 days. However, AGEN stock has declined by -24.15% in the 3 months of the year. Over the past six months meanwhile, it has lost -16.08% and lost -12.78% year-on date.
The market cap for AGEN stock reached $703.61 million, with 182.67 million shares outstanding and 159.54 million shares in the current float. Compared to the average trading volume of 2.04M shares, AGEN reached a trading volume of 10368292 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Agenus Inc. [AGEN]:
B. Riley FBR have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 19, 2019. The new note on the price target was released on April 22, 2019, representing the official price target for Agenus Inc. stock. Previously, the target price had yet another drop from $10 to $5, while H.C. Wainwright kept a Neutral rating on AGEN stock.
The Average True Range (ATR) for Agenus Inc. is set at 0.22, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 7.70.
AGEN stock trade performance evaluation
Agenus Inc. [AGEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.20. With this latest performance, AGEN shares dropped by -6.82% in over the last four-week period, additionally sinking by -16.08% over the last 6 months – not to mention a drop of -7.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 47.00, with the RSI for the last a single of trading hit 48.41, and the three-weeks RSI is set at 46.41 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 3.80, while it was recorded at 3.64 for the last single week of trading, and 3.50 for the last 200 days.
Agenus Inc. [AGEN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Agenus Inc. [AGEN] shares currently have an operating margin of -340.25. Agenus Inc.’s Net Margin is presently recorded at -434.14.
Reflecting on the efficiency of the workforce at the company, Agenus Inc. [AGEN] managed to generate an average of -$543,170 per employee. Receivables Turnover for the company is 35.49 with a Total Asset Turnover recorded at a value of 0.27.Agenus Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 0.90.
Earnings per share (EPS) analysis for Agenus Inc. [AGEN] stock
With the latest financial reports released by the company, Agenus Inc. posted -0.22/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 42.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AGEN.
Agenus Inc. [AGEN]: Insider Ownership positions
There are presently around $362 million, or 54.00% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: BLACKROCK INC. with ownership of 13,481,251, which is approximately 8.372% of the company’s market cap and around 0.40% of the total institutional ownership; ORACLE INVESTMENT MANAGEMENT INC, holding 13,134,900 shares of the stock with an approximate value of $46.63 million in AGEN stocks shares; and RTW INVESTMENTS, LP, currently with $45.67 million in AGEN stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Agenus Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 76 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 18,839,386 shares. Additionally, 57 investors decreased positions by around 7,299,116 shares, while 27 investors held positions by with 75,831,241 shares. The mentioned changes placed institutional holdings at 101,969,743 shares, according to the latest SEC report filing. AGEN stock had 24 new institutional investments in for a total of 2,787,345 shares, while 22 institutional investors sold positions of 1,897,148 shares during the same period.